

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee, 2015
(including the 19th WHO Model List of Essential Medicines
and the 5th WHO Model List of Essential Medicines for Children)



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries).

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order on line: <http://www.who.int/bookorders>).

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee, 2015
(including the 19th WHO Model List of Essential Medicines
and the 5th WHO Model List of Essential Medicines for Children)

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

The selection and use of essential medicines: Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children).

(WHO technical report series ; no. 994)

1. Drugs, Essential – therapeutic use. 2. Drugs, Essential – standards. 3. Drug information services. 4. Drug utilization. 5. Child. I. World Health Organization. II. Series.

ISBN 978 92 4 120994 6

(NLM classification: QV 55)

ISBN (PDF) 978 92 4 069494 1

ISSN 0512-3054

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of a WHO Expert Committee and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Italy

Suggested citation:

The selection and use of essential medicines. Report of the WHO Expert Committee, 2015 (including the 19th WHO Model List of Essential Medicines and the 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2015 (WHO Technical Report Series, No. 994; http://apps.who.int/iris/bitstream/10665/189763/1/9789241209946_eng.pdf).

Contents

Executive summary	vii
List of participants	x
Declaration of interests	xiii
1. Introduction	1
2. Open session	2
3. General items	4
3.1 High-priced medicines	4
3.2 Note on evaluation of “off-label” medicines	7
3.3 Structure and function of the EML Committee and application process	7
3.4 Essential Medicines List for children	8
4. Summary of recommendations	9
Additions to Model Lists	9
Deletions from Model Lists	11
Changes to sections	11
Amended dosage strength and form	11
Reinstatement	12
Rejected applications	12
5. Applications for the 19th Model List of Essential Medicines and the 5th Model List of Essential Medicines for Children	18
Section 2: Medicines for pain and palliative care	18
2.2: Opioid analgesics	18
Morphine – (hydromorphone and oxycodone) (Review) – EML and EMLc	18
Section 5: Anticonvulsants/antiepileptics	19
Magnesium sulfate (review) – EML	19
Midazolam (new indication) – EML and EMLc	20
Valproic acid (sodium valproate) (new formulation) – EML and EMLc	22
Section 6: Anti-infective medicines	26
6.2: Antibacterials	26
6.2.4: Antituberculosis medicines	26
Bedaquiline (addition) – EML	26
Delamanid (addition) – EML	26
Linezolid (addition) – EML and EMLc	26
Terizidone (addition) – EML and EMLc	26
Rifapentine (addition) – EML and EMLc	35
6.3: Antifungal medicines	38
Itraconazole (addition) – EML and EMLc	38
6.4: Antiviral medicines	42
6.4.2: Antiretrovirals	42
Various antiretroviral medicines and/or formulations (deletion) – EML and EMLc	42

6.4.2: Antiretrovirals – fixed-dose combinations	45
Abavacir + lamivudine (addition) – EML and EMLc	45
Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate (addition) – EML	47
Emtricitabine + rilpivirine + tenofovir disoproxil fumarate (addition) – EML	47
6.4.2.2: Non-nucleoside reverse transcriptase inhibitors	50
Efavirenz (EFV or EFZ) (new formulation) – EML and EMLc	50
Nevirapine (NVP) (new formulation) – EML and EMLc	50
6.4.2.3: Protease inhibitors	52
Darunavir (addition) – EML and EMLc	52
6.4.3: Other antivirals	54
Valganciclovir (addition) – EML	54
6.4.4: Anti-hepatitis medicines	56
6.4.4.1: Medicines for hepatitis B	56
Entecavir (addition) – EML and EMLc	56
Tenofovir disoproxil fumarate (new indication) – EML	56
6.4.4.2: Medicines for hepatitis C	60
Sofosbuvir (addition) – EML	60
Daclatasvir (addition) – EML	60
Simeprevir (addition) – EML	60
Ledipasvir + sofosbuvir (addition) – EML	60
Ombitasvir + paritaprevir + ritonavir with or without dasabuvir (addition) – EML	60
Section 8: Antineoplastics and immunosuppressives	75
8.1: Immunosuppressive medicines	75
Azathioprine (new indication) – EML	75
8.2: Cytotoxic and adjuvant medicines & 8.3 Hormones and antihormones	77
Acute myelogenous leukaemia (AML) including Acute promyelocytic leukaemia (APML) – EML	82
Chronic lymphocytic leukaemia (CLL) – EML	94
Chronic myelogenous leukaemia (CML) – EML	102
Diffuse large B-cell lymphoma – EML	109
Early-stage breast cancer – EML	115
Early-stage cervical cancer – EML	125
Early-stage colon cancer – EML	133
Early-stage rectal cancer – EML	141
Early- and advanced-stage head and neck cancers – EML	148
Epithelial ovarian cancer – EML	153
Ewing sarcoma – EMLc	160
Follicular lymphoma – EML	166
Gastrointestinal stromal tumour (GIST) – EML	175
Gestational trophoblastic neoplasia (GTN) – EML	180
Granulocyte colony stimulating factor (G-CSF) (addition) – EML and EMLc	187
Hodgkin lymphoma (adult) – EML	190
Hodgkin lymphoma (paediatric) – EMLc	197
Kaposi sarcoma – EML	204
Metastatic breast cancer – EML	210
Metastatic colorectal cancer – EML	220
Metastatic prostate cancer – EML	227

Nasopharyngeal carcinoma – EML	234
Non-small cell lung cancer – EML	240
Osteosarcoma – EMLc	249
Ovarian germ cell tumours – EML and EMLc	255
Paediatric cancers: Burkitt lymphoma, acute lymphocytic leukaemia (ALL), Wilms tumour – EMLc	261
Retinoblastoma – EMLc	264
Rhabdomyosarcoma – EMLc	272
Testicular germ cell tumours – EML and EMLc	278
Section 9: Antiparkinsonism medicines	285
Dopamine agonists (review) – EML	285
Section 10: Medicines affecting the blood	289
10.1: Antianaemia medicines	289
Folic acid (new formulation) – EML	289
Ferrous salt + folic acid (new formulation) – EML	291
10.2: Medicines affecting coagulation	293
Desmopressin (addition) – EML	293
Low-molecular-weight heparin (addition) – EML	295
Novel oral anticoagulants (NOACs – dabigatran, rivaroxaban, apixaban) (addition) – EML	300
Section 11: Blood products of human origin and plasma substitutes	309
11.2.3: Plasma proteins (new section)	309
Plasma-derived C1 esterase inhibitor (addition) – EML and EMLc	309
Section 12: Cardiovascular medicines	311
12.3: Antihypertensive medicines	311
12.4: Medicines used in heart failure	311
Atenolol (review) – EML	311
12.5: Antithrombotic medicines	314
Clopidogrel (addition) – EML	314
12.7: Fixed-dose combinations of cardiovascular medicines	317
Aspirin + statin + antihypertensive “polypill” (addition) – EML	317
Section 14: Diagnostic agents	321
14.2: Radiocontrast media	321
Gadopentate dimeglumine (addition) – EML	321
Gadoterate meglumine (addition) – EML and EMLc	321
Section 15: Disinfectants and antiseptics	323
15.2: Disinfectants	323
Alcohol-based hand rub (addition) – EML and EMLc	323
Section 17: Gastrointestinal medicines	325
17.1: Antiulcer medicines	325
Omeprazole (new formulation) – EML	325
Section 18: Hormones, other endocrine medicines and contraceptives	330
18.3.3: Intrauterine devices	330
Levonorgestrel-releasing intrauterine system (new formulation) – EML	330
18.3.5: Implantable contraceptives	332
Etonogestrel-releasing implant (addition) – EML	332
18.3.6: Intravaginal contraceptives (new section)	334
Progesterone contraceptive vaginal ring (addition) – EML	334

Section 19: Immunologicals	337
19.3: Vaccines (review) – EML and EMLc	337
Section 21: Ophthalmological preparations	339
21.6: Anti-vascular endothelial growth factor (VEGF) preparations	339
Ranibizumab (addition) – EML	339
Section 22: Oxytocics and antioxytocics	345
22.1: Oxytocics	345
Misoprostol (deletion) for PPH prevention – EML	345
Misoprostol (new indication – treatment of postpartum haemorrhage) – EML	347
References	351
Annex 1	
19th WHO Model List of Essential Medicines (April 2015)	417
Annex 2	
5th WHO Model List of Essential Medicines for Children (April 2015)	471
Annex 3	
The Anatomical Therapeutic Chemical (ATC) Classification System	507
Annex 4	
Alphabetical list of essential medicines (with ATC classification code numbers)	535

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report?>